Windows to New Worlds

Theres Money in the Middle

Welcome to what economists now call the middle skills jobs gap, where theres a dire need for people to fill jobs that require workers with more than a high school diploma but less than a four-year college degree.

Some 69 million people work in middle-skills jobs, representing about 48 percent of the U.S. labor force. That about squares with South Carolina, wheremiddle-skills jobs account for half of all jobs, according to figures from the S.C. Department of Employment and Workforce.

And yet, as baby boomers retire, the middle is also shrinking. According to the Harvard Business Review, as many as 25 million, or 47 percent, of all new job openings from 2010 to 2020 will fall into the middle-skills range.

In other words, theres a great demand for people to fill solid, reliable and well-paying jobs that only require a high-school degree and some additional training of one to two years.

At Midlands Tech, a one-year certificate program runs an average cost of $5,000 for tuition and books; the cost is about $7,500 for a year and a half diploma program, and about $10,000 for a two-year associates degree. Scholarship assistance may be available through either a federal Pell grant (about $5,500 a year) depending on need or S.C. Lottery Tuition Assistance ($2,000), which is available to most applicants. Hot Fields: Health Care, Advanced Manufacturing, IT and Energy Midlands Technical College President Sonny White says there are as many as 12,000 jobs in the Midlands in four cluster areas of health care, advanced manufacturing, information technology and energy.

The boom in middle-skills jobs is reflective of what has long been an economic reality: a four-year college degree no longer guarantees a job. Thats part of the reason, White says, why 80 percent of his students start at age 25 or older. Theyve either gone to college and quit or stuck it out and found their diploma just didnt have that much purchasing power in the modern job market.

Among the top middle-skills jobs in the Midlands, White cites the boom in information technology jobs, particularly ones necessary to Columbias booming insurance industry.

A job as a web developer, network analyst or network administrator requires a two-year associates degree, and generally pays between $35,000 and $100,000 annually. The job prospects are outstanding in our area, White says.

See more here:
Windows to New Worlds

The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences …

Boston, MA (PRWEB) August 29, 2014

A major challenge before new biotechnology start-up companies, especially ones in the biotech start-up dense realm of Boston-Cambridge, is gaining visibility that can lead to important strategic alliances and able investors. James Sherley, the Director of Bostons Adult Stem Cell Technology Center, LLC (ASCTC), has made increasing the local and national visibility of his company an important priority since he started the company in September 2013.

In addition to a social media marketing campaign launched earlier in July of this year, Director Sherley has targeted research and development conferences both nationally and internationally to increase industry awareness of ASCTCs unique portfolio of intellectual property available for licensing and its current commercial development targets. The company is focused on producing two products to address two important needs in drug development and regenerative medicine, respectively, that it is uniquely positioned to address.

ASCTCs most advanced product is an assay that can detect, very early in the drug development pipeline, drug candidates that will ultimately fail because of their toxicity to tissue stem cells. ASCTC developed the new technology in partnership with AlphaSTAR, Corporation, located in Long Beach, California. Currently, such lurking drugs are not detected until after expensive animal testing, more expensive clinical trials, or worse, after marketing. Director Sherley refers to the second product as, A future of pounds and pounds of normal adult tissue stem cells. The company holds a patented technology for mass production of human tissue stem cells. The initial production target is human liver stem cells that can be used to make mature human liver cells for use in drug development and to support liver transplant patients. The company also holds patents for production of pancreatic stem cells and hair follicle stem cells.

The sponsor the 2014 Stem Cells & Regenerative Medicine Conference, in Boston, September 15-16, Terrapinn, Inc., invited ASCTC to attend as a VIP guest. Although ASCTC will not make a formal presentation at this conference, Director Sherley will participate in a roundtable discussion on the topic, Articulating value for up-and-coming regenerative medicine, stem cell and cell-based therapies.

Later in September (22-24), Director Sherley will present one of the selected Next Generation Presentations for new companies at BioPharm America 2014, also taking place in Boston. In addition to the public presentation, ASCTC will also participate in confidential partnering meetings with potential investors and strategic alliance partners arranged by conference organizers.

In October, Director Sherley will present to a primarily academic research audience a more detailed accounting of ASCTCs computer simulation technology for quantifying tissue stem cells in culture. This technology is the basis for the companys new assay for tissue stem cell toxicity. Director Sherley is particularly interested in the response from several experts in tissue stem cell growth dynamics who are invited speakers. The symposium, which will take place at Rhode Island Hospital, a medical affiliate of Brown University in Providence, has the goal of presenting emerging disruptive research in the area of Novel Stem Cells and Vesicles. Director Sherley is a member of the symposium organizing committee. ************************************************************************************************************* The Adult Stem Cell Technology Center, LLC (ASCTC) is a Massachusetts life sciences company established in September 2013. ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing iPSCs. Currently, ASCTC is employing its technological advantages to pursue commercialization of mass-produced therapeutic human liver cells and facile assays that are early warning systems for drug candidates with catastrophic toxicity due to adverse effects against adult tissue stem cells.

Here is the original post:
The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences …

New Tool Aids Stem Cell Engineering for Medical Research

Released: 28-Aug-2014 12:20 PM EDT Source Newsroom: Mayo Clinic Contact Information

Available for logged-in reporters only

Newswise ROCHESTER, Minn. A Mayo Clinic researcher and his collaborators have developed an online analytic tool that will speed up and enhance the process of re-engineering cells for biomedical investigation. CellNet is a free-use Internet platform that uses network biology methods to aid stem cell engineering. Details of CellNet and its application to stem cell engineering are described in two back-to-back papers in the journal Cell.

This free platform has a broad range of uses for all types of cell-based investigations and can potentially offer help to people working on all types of cancer, says Hu Li, Ph.D., investigator in the Mayo Clinic Center for Individualized Medicine and Department of Molecular Pharmacology & Experimental Therapeutics, and co-lead investigator in the two works. CellNet will indicate how closely an engineered cell resembles the real counterpart and even suggests ways to adjust the engineering.

The network biology platform contains data on a wide range of cells and details on what is known about those cell types. Researchers say the platform can be applied to almost any study and allows users to refine the engineering process. In the long term, it should provide a reliable short cut to the early phases of drug development, individualized cancer therapies, and pharmacogenetics.

CellNet uses 21 cell types and tissues and data from 56 published human and mouse engineering studies as a basis for analyzing and predicting cell fate and corresponding engineering strategies. The platform also offers classification scores to determine differentiation and conversion of induced pluripotent stem cells. It reveals incomplete conversion of engineered microphages and hepatocytes. CellNet can be used for interrogation of cell fate following expression profiling, by classifying input by cell type, quantifying gene regulatory network status, and identifying aberrant regulators affecting the engineering process. All this is valuable in predicting success of engraftment of cancer tumors in mouse avatars for cancer and drug development research. CellNet can be accessed at cellnet.hms.harvard.edu.

Co-lead authors with Dr. Li are Patrick Cahan, Ph.D., and Samantha Morris, Ph.D., of Boston Children’s Hospital. The senior investigators are George Q. Daley, M.D., Ph.D., Director of the Stem Cell Transplantation Program at Boston Children’s and senior investigator on both studies and James Collins, Ph.D., Core Faculty member at the Wyss Institute and the William F. Warren Distinguished Professor at Boston University, co-senior investigator on one of the studies.

Investigators are supported in part by the National Institutes of Health, specifically, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute; the Children’s Hospital Stem Cell Program; the Howard Hughes Medical Institute; Alex’s Lemonade Stand Foundation; the Ellison Medical Foundation; the Doris Duke Medical Foundation; the Mayo Clinic Center for Individualized Medicine and the Mayo Clinic Center for Regenerative Medicine.

###

About Mayo ClinicMayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.

More:
New Tool Aids Stem Cell Engineering for Medical Research

Stem Cell Activation Phuket, Thailand: How is your stem cell therapy different – Video



Stem Cell Activation Phuket, Thailand: How is your stem cell therapy different
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-is-your-stem-cell-therapy-different/ Thanyapura Health offers natural stem cell activation,…

By: Thanyapura Health Centre

Follow this link:
Stem Cell Activation Phuket, Thailand: How is your stem cell therapy different – Video

Stem Cell Activation Phuket, Thailand: How have athletes been using stem cell therapy – Video



Stem Cell Activation Phuket, Thailand: How have athletes been using stem cell therapy
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-have-athletes-been-using-stem-cell-therapy/ Using stem cell therapy treats body issue e.g….

By: Thanyapura Health Centre

Go here to see the original:
Stem Cell Activation Phuket, Thailand: How have athletes been using stem cell therapy – Video

Stem Cell Activation Phuket: What type of clients have you been seeing for stem cell therapy – Video



Stem Cell Activation Phuket: What type of clients have you been seeing for stem cell therapy
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/what-type-of-clients-have-you-been-seeing-for-stem-cell-therapy/ Wide range of client who has…

By: Thanyapura Health Centre

Read the original here:
Stem Cell Activation Phuket: What type of clients have you been seeing for stem cell therapy – Video

Jilly’s Miracle post stem cell therapy at Australind Veterinary Hospital – Video



Jilly's Miracle post stem cell therapy at Australind Veterinary Hospital
Jilly pain free following stem cell therapy at Australind Veterinary Hospital.

By: AustralindVet

View post:
Jilly’s Miracle post stem cell therapy at Australind Veterinary Hospital – Video

Boy Scout Troop 286 Icebucket Challenge for the Scoutmaster – Video



Boy Scout Troop 286 Icebucket Challenge for the Scoutmaster
Ice Bucket Challenge Completed! With a whole lot of help from my Scouts! Donation went to the Midwest Stem Cell Therapy Center at KU Med in Kansas City. They do some terrific work there and…

By: Scott Medlock

Read the original:
Boy Scout Troop 286 Icebucket Challenge for the Scoutmaster – Video

Cesca Therapeutics Advocates Benefits of Cell Therapy to the Centers for Medicare and Medicaid Services

RANCHO CORDOVA, Calif. — Cesca Therapeutics Inc. , an autologous cell-based regenerative medicine company, today announced the presentation to the Centers for Medicare and Medicaid Services ("CMS") …

More here:
Cesca Therapeutics Advocates Benefits of Cell Therapy to the Centers for Medicare and Medicaid Services

Advanced Cell Technology Announces 1:100 Reverse Stock Split

Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced that it has completed a 1:100 reverse split of its common stock

Read this article:
Advanced Cell Technology Announces 1:100 Reverse Stock Split